About DUB Therapeutics

Founded in March 2022, DUB Therapeutics emerged from decades of pioneering research. Our scientific foundation is built on the discovery of a novel class of enzymes whose activity controls protein degradation and influences the stages of wound healing to promote tissue regeneration.

We've developed a proprietary self-delivering siRNA (sdRNA) platform that targets these critical pathways. Our lead programs focus on ocular surface diseases where the cornea's unique biology—a highly organized tissue that must maintain transparency while healing— presents both significant challenges and opportunities for breakthrough treatments.

In 2023, our work gained significant recognition with $3M USD in funding to advance the first ophthalmology program. This support significantly advanced our regulatory development culminating in the completion of an FDA INTERACT meeting December 2024. In 2025, the completion of these milestones led to a $1M USD investment by Upstate Biotech Ventures and a second Direct to Phase II NIH grant for the second ophthalmology program in development.

While our current focus addresses critical unmet needs in ocular therapeutics, our vision extends to the broader landscape of fibrotic diseases affecting patients worldwide. We're advancing multiple programs through pre-clinical development with clinical trials planned for 2027, as we work to transform what was once considered "undruggable" targets into conditions treatable with sdRNA technology.